Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $22.8 million.

  • Seres Therapeutics' Operating Expenses fell 2174.15% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.8 million, marking a year-over-year decrease of 1986.29%. This contributed to the annual value of $121.3 million for FY2024, which is 3781.81% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Operating Expenses is $22.8 million, which was down 2174.15% from $24.9 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Operating Expenses high stood at $76.9 million for Q2 2023, and its period low was -$4.4 million during Q4 2022.
  • Moreover, its 5-year median value for Operating Expenses was $41.0 million (2021), whereas its average is $42.9 million.
  • As far as peak fluctuations go, Seres Therapeutics' Operating Expenses plummeted by 10780.54% in 2022, and later surged by 93726.82% in 2023.
  • Over the past 5 years, Seres Therapeutics' Operating Expenses (Quarter) stood at $56.7 million in 2021, then plummeted by 107.81% to -$4.4 million in 2022, then surged by 937.27% to $37.0 million in 2023, then dropped by 22.12% to $28.8 million in 2024, then dropped by 20.83% to $22.8 million in 2025.
  • Its last three reported values are $22.8 million in Q3 2025, $24.9 million for Q2 2025, and $27.2 million during Q1 2025.